RAD 202 receives approval to start Phase 1 therapeutic trial December 20, 2024 Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on investingnews.com admin December 20, 2024 Previous Article Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation Next Article PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
